Buy
Average AnalystBuy
Top AnalystSlightly Bearish
Stock Target AdvisorBuy
Average UserUSD 30.37
+1.59 (+5.52%)
USD 4.10B
1.99M
USD 53.59(+76.47%)
Based on the Apellis Pharmaceuticals Inc stock forecast from 18 analysts, the average analyst target price for Apellis Pharmaceuticals Inc is USD 53.59 over the next 12 months. Apellis Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Apellis Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Apellis Pharmaceuticals Inc’s stock price was USD 30.37. Apellis Pharmaceuticals Inc’s stock price has changed by +3.05% over the past week, -9.23% over the past month and -55.44% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.